| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
| Multiple Sclerosis | 29 | 2021 | 2600 | 3.86 | Why? |
| Multiple Sclerosis, Relapsing-Remitting | 10 | 2019 | 529 | 2.35 | Why? |
| Multiple Sclerosis, Chronic Progressive | 4 | 2017 | 136 | 1.49 | Why? |
| Immunosuppressive Agents | 11 | 2021 | 6331 | 1.13 | Why? |
| Fingolimod Hydrochloride | 5 | 2021 | 217 | 1.12 | Why? |
| Disability Evaluation | 10 | 2019 | 671 | 1.02 | Why? |
| Brain | 11 | 2019 | 5133 | 0.90 | Why? |
| Research Design | 4 | 2017 | 5830 | 0.82 | Why? |
| Disease Progression | 13 | 2021 | 13580 | 0.75 | Why? |
| Cladribine | 1 | 2017 | 65 | 0.65 | Why? |
| Cerebellum | 1 | 2017 | 119 | 0.62 | Why? |
| Magnetic Resonance Imaging | 13 | 2019 | 6551 | 0.60 | Why? |
| Network Meta-Analysis | 1 | 2017 | 426 | 0.56 | Why? |
| Clinical Trials as Topic | 4 | 2017 | 7330 | 0.55 | Why? |
| Sample Size | 1 | 2017 | 518 | 0.55 | Why? |
| Leukoencephalopathy, Progressive Multifocal | 3 | 2019 | 55 | 0.51 | Why? |
| Rituximab | 1 | 2021 | 1096 | 0.50 | Why? |
| Organ Size | 4 | 2018 | 384 | 0.50 | Why? |
| Immunologic Factors | 4 | 2021 | 4206 | 0.46 | Why? |
| Interferons | 2 | 2021 | 2885 | 0.45 | Why? |
| Natalizumab | 3 | 2021 | 144 | 0.40 | Why? |
| Hematopoietic Stem Cell Transplantation | 4 | 2017 | 2426 | 0.39 | Why? |
| Precision Medicine | 1 | 2019 | 1477 | 0.37 | Why? |
| Gadolinium | 1 | 2009 | 318 | 0.36 | Why? |
| Spinal Cord | 3 | 2017 | 281 | 0.35 | Why? |
| Diffusion Magnetic Resonance Imaging | 3 | 2017 | 317 | 0.33 | Why? |
| Antibodies, Monoclonal, Humanized | 4 | 2021 | 9335 | 0.33 | Why? |
| White Matter | 4 | 2018 | 369 | 0.33 | Why? |
| Research Personnel | 1 | 2017 | 1037 | 0.32 | Why? |
| Upper Extremity | 2 | 2019 | 193 | 0.31 | Why? |
| Atrophy | 4 | 2018 | 192 | 0.29 | Why? |
| Muscular Dystrophy, Duchenne | 2 | 2018 | 129 | 0.26 | Why? |
| Drug Monitoring | 1 | 2009 | 1408 | 0.22 | Why? |
| Dimethyl Fumarate | 1 | 2021 | 116 | 0.21 | Why? |
| Methylprednisolone | 3 | 2021 | 2107 | 0.20 | Why? |
| Biomarkers | 4 | 2018 | 23361 | 0.20 | Why? |
| Spinal Muscular Atrophies of Childhood | 1 | 2019 | 7 | 0.20 | Why? |
| Breast Density | 1 | 2018 | 5 | 0.20 | Why? |
| Europe, Eastern | 1 | 2018 | 88 | 0.19 | Why? |
| Ultrasonography, Mammary | 1 | 2018 | 31 | 0.19 | Why? |
| Transplantation, Autologous | 2 | 2017 | 364 | 0.19 | Why? |
| Severity of Illness Index | 6 | 2021 | 48226 | 0.19 | Why? |
| Axons | 1 | 2018 | 73 | 0.18 | Why? |
| Retrograde Degeneration | 1 | 2017 | 1 | 0.18 | Why? |
| Muscular Atrophy, Spinal | 1 | 2019 | 68 | 0.18 | Why? |
| Huntington Disease | 1 | 2018 | 47 | 0.18 | Why? |
| Fingers | 2 | 2018 | 221 | 0.18 | Why? |
| Imaging, Three-Dimensional | 3 | 2018 | 680 | 0.18 | Why? |
| Evoked Potentials, Visual | 1 | 2017 | 40 | 0.18 | Why? |
| Humans | 60 | 2021 | 930598 | 0.17 | Why? |
| Neurofilament Proteins | 1 | 2018 | 202 | 0.17 | Why? |
| Immune Reconstitution Inflammatory Syndrome | 1 | 2017 | 66 | 0.17 | Why? |
| Therapeutics | 1 | 2017 | 35 | 0.17 | Why? |
| Statistics as Topic | 2 | 2017 | 370 | 0.16 | Why? |
| Italy | 9 | 2021 | 38444 | 0.16 | Why? |
| Brain Mapping | 1 | 2017 | 228 | 0.16 | Why? |
| Movement Disorders | 1 | 2018 | 186 | 0.15 | Why? |
| Adult | 31 | 2021 | 244371 | 0.15 | Why? |
| Healthy Aging | 1 | 2017 | 147 | 0.15 | Why? |
| Motor Activity | 1 | 2017 | 217 | 0.15 | Why? |
| Walk Test | 1 | 2018 | 461 | 0.15 | Why? |
| Optic Neuritis | 1 | 2017 | 132 | 0.15 | Why? |
| Latin America | 1 | 2021 | 1721 | 0.15 | Why? |
| Regression Analysis | 2 | 2016 | 2484 | 0.15 | Why? |
| Symptom Flare Up | 1 | 2019 | 432 | 0.14 | Why? |
| Demyelinating Diseases | 1 | 2017 | 224 | 0.14 | Why? |
| Protective Factors | 1 | 2021 | 1720 | 0.14 | Why? |
| Longitudinal Studies | 7 | 2019 | 9893 | 0.14 | Why? |
| Transplantation Conditioning | 1 | 2017 | 323 | 0.14 | Why? |
| Middle Aged | 29 | 2021 | 270681 | 0.14 | Why? |
| Steroids | 2 | 2017 | 904 | 0.14 | Why? |
| Myelin Sheath | 1 | 2014 | 41 | 0.14 | Why? |
| Recurrence | 3 | 2019 | 3675 | 0.14 | Why? |
| Hereditary Autoinflammatory Diseases | 1 | 2015 | 72 | 0.14 | Why? |
| Clinical Trials, Phase II as Topic | 1 | 2017 | 801 | 0.13 | Why? |
| Meta-Analysis as Topic | 1 | 2021 | 1289 | 0.13 | Why? |
| Drug Substitution | 1 | 2017 | 385 | 0.13 | Why? |
| Leukoencephalopathies | 1 | 2017 | 230 | 0.13 | Why? |
| Hand | 1 | 2018 | 449 | 0.13 | Why? |
| Female | 36 | 2021 | 380317 | 0.13 | Why? |
| Brain Injuries, Traumatic | 1 | 2018 | 381 | 0.13 | Why? |
| Graft vs Host Disease | 1 | 2017 | 501 | 0.13 | Why? |
| Plasmapheresis | 1 | 2017 | 437 | 0.13 | Why? |
| Treatment Outcome | 7 | 2021 | 51732 | 0.13 | Why? |
| Amyotrophic Lateral Sclerosis | 1 | 2018 | 398 | 0.12 | Why? |
| Male | 34 | 2021 | 367725 | 0.12 | Why? |
| Interleukin 1 Receptor Antagonist Protein | 1 | 2021 | 1165 | 0.12 | Why? |
| Anti-Inflammatory Agents | 3 | 2021 | 6153 | 0.12 | Why? |
| Magnetic Resonance Spectroscopy | 1 | 2017 | 881 | 0.12 | Why? |
| Neuropsychological Tests | 1 | 2017 | 954 | 0.12 | Why? |
| Young Adult | 14 | 2021 | 93724 | 0.12 | Why? |
| Adolescent | 15 | 2021 | 86841 | 0.12 | Why? |
| Receptors, Interleukin-6 | 1 | 2020 | 1383 | 0.12 | Why? |
| Positron-Emission Tomography | 1 | 2017 | 802 | 0.12 | Why? |
| Cognition Disorders | 1 | 2017 | 574 | 0.12 | Why? |
| Healthy Volunteers | 1 | 2017 | 1444 | 0.11 | Why? |
| Radiographic Image Interpretation, Computer-Assisted | 1 | 2018 | 869 | 0.11 | Why? |
| Plasma Exchange | 1 | 2017 | 763 | 0.11 | Why? |
| Patient Compliance | 1 | 2020 | 1468 | 0.10 | Why? |
| Multivariate Analysis | 1 | 2021 | 5440 | 0.10 | Why? |
| Bipolar Disorder | 1 | 2018 | 744 | 0.10 | Why? |
| Aging | 2 | 2018 | 3581 | 0.10 | Why? |
| Hospitalization | 1 | 2021 | 54280 | 0.10 | Why? |
| Observational Studies as Topic | 1 | 2017 | 1887 | 0.09 | Why? |
| Anisotropy | 2 | 2018 | 56 | 0.09 | Why? |
| Immunomodulation | 1 | 2018 | 1472 | 0.09 | Why? |
| Prognosis | 5 | 2017 | 32490 | 0.09 | Why? |
| Image Processing, Computer-Assisted | 1 | 2016 | 1383 | 0.09 | Why? |
| Evidence-Based Medicine | 2 | 2018 | 3228 | 0.08 | Why? |
| Early Detection of Cancer | 1 | 2018 | 1956 | 0.08 | Why? |
| Follow-Up Studies | 4 | 2020 | 17020 | 0.08 | Why? |
| Databases, Factual | 2 | 2018 | 6248 | 0.08 | Why? |
| Parkinson Disease | 1 | 2018 | 1414 | 0.08 | Why? |
| Registries | 2 | 2017 | 12327 | 0.08 | Why? |
| Neurology | 1 | 2018 | 1613 | 0.08 | Why? |
| Guillain-Barre Syndrome | 1 | 2018 | 1495 | 0.07 | Why? |
| Randomized Controlled Trials as Topic | 2 | 2018 | 10649 | 0.07 | Why? |
| Canada | 1 | 2018 | 6018 | 0.07 | Why? |
| Glucocorticoids | 1 | 2021 | 4431 | 0.07 | Why? |
| France | 1 | 2021 | 12074 | 0.07 | Why? |
| Time Factors | 3 | 2018 | 31397 | 0.07 | Why? |
| Dementia | 1 | 2018 | 1861 | 0.07 | Why? |
| Europe | 2 | 2018 | 12702 | 0.07 | Why? |
| Double-Blind Method | 1 | 2016 | 5988 | 0.07 | Why? |
| Cohort Studies | 8 | 2021 | 36005 | 0.07 | Why? |
| Risk | 1 | 2017 | 5288 | 0.07 | Why? |
| Mortality | 1 | 2021 | 7132 | 0.07 | Why? |
| Aged | 12 | 2021 | 215776 | 0.07 | Why? |
| Alendronate | 1 | 2002 | 12 | 0.06 | Why? |
| Practice Guidelines as Topic | 2 | 2018 | 15421 | 0.06 | Why? |
| Consensus | 1 | 2018 | 6345 | 0.06 | Why? |
| Retrospective Studies | 8 | 2021 | 105322 | 0.06 | Why? |
| Patient Selection | 1 | 2017 | 4560 | 0.06 | Why? |
| Immunoassay | 1 | 2018 | 4485 | 0.06 | Why? |
| Bone Resorption | 1 | 2002 | 61 | 0.06 | Why? |
| Societies, Medical | 1 | 2018 | 6907 | 0.06 | Why? |
| Aged, 80 and over | 6 | 2021 | 88759 | 0.05 | Why? |
| Walking | 2 | 2019 | 442 | 0.05 | Why? |
| Age Factors | 3 | 2017 | 21039 | 0.05 | Why? |
| Breast Neoplasms | 1 | 2018 | 3633 | 0.05 | Why? |
| Injections, Intravenous | 1 | 2021 | 381 | 0.05 | Why? |
| Pneumonia, Viral | 4 | 2020 | 243684 | 0.05 | Why? |
| Kaplan-Meier Estimate | 2 | 2021 | 4260 | 0.05 | Why? |
| Coronavirus Infections | 4 | 2020 | 253789 | 0.05 | Why? |
| Respiratory Insufficiency | 1 | 2020 | 7301 | 0.05 | Why? |
| Diffusion Tensor Imaging | 1 | 2018 | 125 | 0.04 | Why? |
| Betacoronavirus | 4 | 2020 | 204454 | 0.04 | Why? |
| Respiration, Artificial | 2 | 2021 | 22116 | 0.04 | Why? |
| Psychomotor Performance | 1 | 2018 | 110 | 0.04 | Why? |
| Biopsy, Needle | 1 | 2018 | 303 | 0.04 | Why? |
| Cardiovascular Abnormalities | 1 | 2017 | 72 | 0.04 | Why? |
| Intensive Care Units | 2 | 2021 | 29594 | 0.04 | Why? |
| Tumor Burden | 1 | 2018 | 369 | 0.04 | Why? |
| Child, Preschool | 7 | 2019 | 36283 | 0.04 | Why? |
| Darunavir | 1 | 2020 | 477 | 0.04 | Why? |
| Joint Diseases | 1 | 1998 | 122 | 0.04 | Why? |
| Optic Nerve | 1 | 2017 | 123 | 0.04 | Why? |
| HIV Protease Inhibitors | 1 | 2020 | 434 | 0.04 | Why? |
| Early Medical Intervention | 1 | 2020 | 487 | 0.04 | Why? |
| Gray Matter | 1 | 2017 | 150 | 0.04 | Why? |
| Child | 9 | 2019 | 70012 | 0.04 | Why? |
| Lymphatic Metastasis | 1 | 2018 | 537 | 0.04 | Why? |
| Pandemics | 8 | 2021 | 389249 | 0.04 | Why? |
| Touch | 1 | 2017 | 180 | 0.04 | Why? |
| Mevalonate Kinase Deficiency | 1 | 2015 | 10 | 0.04 | Why? |
| Cryopyrin-Associated Periodic Syndromes | 1 | 2015 | 20 | 0.04 | Why? |
| Personal Protective Equipment | 1 | 2020 | 15978 | 0.04 | Why? |
| Spinal Diseases | 1 | 1998 | 238 | 0.04 | Why? |
| PubMed | 1 | 2017 | 246 | 0.04 | Why? |
| Stroke | 1 | 2018 | 8839 | 0.04 | Why? |
| Risk Factors | 2 | 2021 | 71621 | 0.04 | Why? |
| Reference Standards | 1 | 2019 | 1163 | 0.03 | Why? |
| Monitoring, Ambulatory | 1 | 2018 | 343 | 0.03 | Why? |
| Familial Mediterranean Fever | 1 | 2015 | 88 | 0.03 | Why? |
| Drug Administration Schedule | 1 | 2021 | 2324 | 0.03 | Why? |
| Statistics, Nonparametric | 1 | 2017 | 1008 | 0.03 | Why? |
| False Positive Reactions | 1 | 2018 | 1338 | 0.03 | Why? |
| Respiratory Function Tests | 1 | 2020 | 1755 | 0.03 | Why? |
| Retina | 1 | 2017 | 424 | 0.03 | Why? |
| ROC Curve | 2 | 2015 | 6024 | 0.03 | Why? |
| Withholding Treatment | 1 | 2018 | 798 | 0.03 | Why? |
| Metabolic Diseases | 1 | 2017 | 505 | 0.03 | Why? |
| Disease-Free Survival | 1 | 2017 | 1654 | 0.03 | Why? |
| Tomography, X-Ray Computed | 1 | 2018 | 25144 | 0.03 | Why? |
| United States | 1 | 2018 | 46150 | 0.03 | Why? |
| Linear Models | 1 | 2017 | 1914 | 0.03 | Why? |
| Dose-Response Relationship, Drug | 1 | 2020 | 3776 | 0.03 | Why? |
| Demography | 1 | 2017 | 1660 | 0.03 | Why? |
| Reproducibility of Results | 3 | 2018 | 11304 | 0.03 | Why? |
| Telemedicine | 1 | 2021 | 25032 | 0.02 | Why? |
| Tomography, Optical Coherence | 1 | 2017 | 1008 | 0.02 | Why? |
| Prospective Studies | 3 | 2021 | 43301 | 0.02 | Why? |
| Infant | 3 | 2017 | 30274 | 0.02 | Why? |
| Pregnenediones | 1 | 2011 | 182 | 0.02 | Why? |
| Crohn Disease | 1 | 1998 | 959 | 0.02 | Why? |
| Colitis, Ulcerative | 1 | 1998 | 1037 | 0.02 | Why? |
| Aftercare | 1 | 2018 | 1637 | 0.02 | Why? |
| Antimalarials | 1 | 2020 | 2505 | 0.02 | Why? |
| Prednisolone | 1 | 2011 | 443 | 0.02 | Why? |
| Sensitivity and Specificity | 3 | 2018 | 22971 | 0.02 | Why? |
| Bayes Theorem | 1 | 2017 | 3237 | 0.02 | Why? |
| Delayed Diagnosis | 1 | 2017 | 1529 | 0.02 | Why? |
| Rheumatic Diseases | 1 | 2002 | 2675 | 0.02 | Why? |
| Disabled Persons | 1 | 2017 | 1152 | 0.02 | Why? |
| Software | 1 | 2017 | 2501 | 0.02 | Why? |
| Ritonavir | 1 | 2020 | 4212 | 0.02 | Why? |
| Health Status | 1 | 2019 | 3259 | 0.02 | Why? |
| Acute Disease | 1 | 2017 | 6029 | 0.02 | Why? |
| C-Reactive Protein | 1 | 2021 | 7972 | 0.02 | Why? |
| Cross-Sectional Studies | 3 | 2018 | 53120 | 0.02 | Why? |
| Survival Analysis | 1 | 2017 | 7592 | 0.02 | Why? |
| International Cooperation | 1 | 2017 | 3436 | 0.02 | Why? |
| Surveys and Questionnaires | 2 | 2021 | 43792 | 0.02 | Why? |
| Internet | 1 | 2021 | 6204 | 0.02 | Why? |
| Diagnosis, Differential | 1 | 2017 | 7220 | 0.01 | Why? |
| Anthropometry | 1 | 2002 | 233 | 0.01 | Why? |
| Algorithms | 1 | 2019 | 7346 | 0.01 | Why? |
| Lumbar Vertebrae | 1 | 2002 | 196 | 0.01 | Why? |
| Sex Factors | 1 | 2017 | 11014 | 0.01 | Why? |
| Bone Density | 1 | 2002 | 335 | 0.01 | Why? |
| Technetium Tc 99m Exametazime | 1 | 1998 | 3 | 0.01 | Why? |
| Nervous System Diseases | 1 | 2017 | 4092 | 0.01 | Why? |
| Fever | 1 | 2015 | 7795 | 0.01 | Why? |
| Radionuclide Imaging | 1 | 1998 | 184 | 0.01 | Why? |
| Incidence | 1 | 2018 | 25622 | 0.01 | Why? |
| Hydroxychloroquine | 1 | 2020 | 12447 | 0.01 | Why? |
| Infant, Newborn | 1 | 2017 | 23105 | 0.01 | Why? |
| Case-Control Studies | 1 | 2015 | 17671 | 0.01 | Why? |
| Mental Disorders | 1 | 2017 | 6742 | 0.01 | Why? |
| Radiography | 1 | 2002 | 1576 | 0.01 | Why? |
| Comorbidity | 1 | 2017 | 34796 | 0.01 | Why? |
| Antiviral Agents | 1 | 2020 | 41703 | 0.01 | Why? |
| Predictive Value of Tests | 1 | 1998 | 9537 | 0.00 | Why? |